The relevance of HDAC6–STAT3 signaling in immunomodulatory pathways in CRC has been confirmed by the pharmacological inhibition of HDAC6 that led to reduced functionality of STAT3 signaling, impacting the expression of genes involved in the inflammatory and immune responses [140]. The gene discussed is STAT3; the disease is colorectal carcinoma.